Some key points outside of the presentation slides:
The Osiris deal more than doubled Mesoblast's patent suite.
Type 2 diabetes Ph2 results are to be announced in the coming weeks.
Spinal fusion Ph3 trial commencement will announced shortly.
Degenerative disk repair interim results to be released shortly and Ph3 trial should commence in 2014.
The heart trial will be conducted by teva and the endpoint will be time to first event analysis - ie. time to hospitalisation or death. The most effective dosage from Ph2 results will be used. If the trial replicates results anywhere near the Ph2 results the trial will be a success.
Stroke: the current available treatment must be administered within 3 hours of the stroke. MPCs can be administered within 7 days of the stroke based on the rat study. (Read that again!) A program will be built over the next 12 months.
GVHD expanded access program makes Prochymal currently available to physicians requesting it to treat children in the US. Silviu said the Ph3 results were "amazing". Mesoblast is currently being inundated with requests for Prochymal in the US.
Finally, JCR will file for GVHD product approval in Japan by end of Q1 2014.
GLTAH!
agm summary
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.020(1.87%) |
Mkt cap ! $1.241B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.00M | 10.05M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3906 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 13574 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.020 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |